Intira Sriprasert

Dr. Intira Sriprasert

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
VCVictoria K. Cortessis
Victoria K. Cortessis
MAMoosa Azadian
Moosa Azadian
JBJames Buxbaum
James Buxbaum
FSFatimata Sanogo
Fatimata Sanogo
ASAshley Y. Song
Ashley Y. Song
KSKimberly D. Siegmund
Kimberly D. Siegmund

24 July 2017 in Contraception and Reproductive Medicine
Verified
Journal Article
Open access
PDF file
ISIntira Sriprasert
Intira Sriprasert
TPTarita Pakrashi
Tarita Pakrashi
TKThomas Kimble
Thomas Kimble
DADavid F. Archer
David F. Archer
Heavy menstrual bleeding (HMB) is a common gynecological problem that has a significant impact on a woman’s quality of life and the activities of daily living. Due to the difficulty in accurately describing menstrual bleeding abnormalities using older terminology, the PALM-COEIN classification system of the Federation Internationale de Gynecologie et d’Obstetrique was proposed to describe and identify the etiology of abnormal endometrial bleeding. As there is no single pathway that is associated with HMB, there are several therapeutic interventions involving different molecular pathways to reduce HMB. This article will highlight the current evidence as it relates to the etiology of HMB as well as medical modalities of treatment.

1 May 2015 in Contraception
Verified
Journal Article
Closed access
ADAnh Dinh
Anh Dinh
ISIntira Sriprasert
Intira Sriprasert
AWAlistair R. Williams
Alistair R. Williams
DADavid F. Archer
David F. Archer

1 March 2016 in Menopause
Verified
Journal Article
Closed access
ISIntira Sriprasert
Intira Sriprasert
DWDwight W. Warren
Dwight W. Warren
AMAustin K. Mircheff
Austin K. Mircheff
FSFrank Z. Stanczyk
Frank Z. Stanczyk
This review examines the etiology and pathophysiology of dry eye disease in postmenopausal women, and describes the steroid reproductive hormone influences that may contribute to its development. We have reviewed the relevant studies on dry eye disease related to hormonal status and hormone therapy (HT) in both animal models and humans. Although both low and high estrogen levels have been associated with symptoms of dry eye disease, low androgen levels are a more consistent factor in its etiology. Postmenopausal HT with estrogen or estrogen plus progestogen has shown a limited benefit for dry eye symptoms and may even result in progression of meibomian gland dysfunction, decreased tear film break up time, and tear flow reduction. However, systemic or local androgen treatment has shown promising results in improving dry eye symptoms. Because of the high incidence of dry eye among postmenopausal women that may be related to the hormonal treatment, we propose that a multidisciplinary approach should be considered between gynecologists and ophthalmologists in management of this disorder.

1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ISIntira Sriprasert
Intira Sriprasert
SSSuparerk Suerungruang
Suparerk Suerungruang
PAPorntip Athilarp
Porntip Athilarp
AMAnuchart Matanasarawoot
Anuchart Matanasarawoot
STSupanimit Teekachunhatean
Supanimit Teekachunhatean
This open-label randomized controlled trial was designed to compare the efficacy of acupuncture and combined oral contraceptive (COC) pill in treating moderate-to-severe primary dysmenorrhea. Fifty-two participants were randomly assigned to receive either acupuncture (n= 27) or COC (n= 25) for three menstrual cycles. Mefenamic acid was prescribed as a recue analgesic drug with both groups. The statistical approach used for efficacy and safety assessments was intention-to-treat analysis. By the end of the study, both treatments had resulted in significant improvement over baselines in all outcomes, that is, maximal dysmenorrhea pain scores, days suffering from dysmenorrhea, amount of rescue analgesic used, and quality of life assessed by SF-36 questionnaire. Over the three treatment cycles, COC caused greater reduction in maximal pain scores than acupuncture, while improvements in the remaining outcomes were comparable. Responders were defined as participants whose maximal dysmenorrhea pain scores decreased at least 33% below their baseline. Response rates following both interventions at the end of the study were not statistically different. Acupuncture commonly caused minimal local side effects but did not cause any hormone-related side effects as did COC. In conclusion, acupuncture is an alternative option for relieving dysmenorrhea, especially when COC is not a favorable choice.

28 September 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
ISIntira Sriprasert
Intira Sriprasert
HHHoward N Hodis
Howard N Hodis
RKRoksana Karim
Roksana Karim
FSFrank Z Stanczyk
Frank Z Stanczyk
DSDonna Shoupe
Donna Shoupe
WMWendy Mack
Wendy Mack
Context The Early versus Late Intervention Trial with Estradiol (ELITE) showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late postmenopause. Objective This post-trial analysis determined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) compared with late (≥10 years) postmenopause. Design Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov number NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. Setting Los Angeles, California, USA Participants Healthy postmenopausal women Intervention Oral E2 with/without cyclic vaginal progesterone Main outcome measures Plasma E2 levels and CIMT assessed every 6 months over an average 4.8 years. Results Among 596 postmenopausal women, higher E2 was inversely associated with CIMT progression in early-postmenopausal women (p=0.041) and positively associated with CIMT progression in late-postmenopausal women (p=0.006) (p-for-interaction<0.001). CIMT progression rate for the lowest versus highest quartiles of E2 levels among early-postmenopausal women was 8.5 μm/yr and 7.2 μm/yr, while among late-postmenopausal women was 9.8 μm/yr and 11.7 μm/yr, respectively. Conclusion E2 levels are differentially associated with atherosclerosis progression according to timing of hormone therapy initiation. With higher E2 levels, CIMT progression rate is decreased among early-postmenopausal women, but increased among late-postmenopausal women. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early postmenopause.